Quarterly Activities/Appendix 4C Cash Flow Report

• FebriDx® sales in Q2 up 4.3x over the previous corresponding quarter (pcp). US December quarter sales were 93% of total sales in FY25. • FebriDx® – FDA has suggested minor updates to the user instructions and an evaluation with representative operators to assess effectiveness, , which have been completed. Positive interaction with FDA suggests we are still working toward CLIA waiver by the end o